Dr. McClure is a consulting Chief Medical Officer (CMO) of Primmune Therapeutics. Dr. McClure has been a CMO at multiple companies over the past nearly seven years and has more than 20 years of clinical and drug development experience with significant expertise in the design, execution and interpretation of Phase 1-3 clinical trials across a broad range of therapeutic areas, including chronic viral hepatitis. Dr. McClure has played a central role in developing multiple drugs, including several which are currently marketed.
Previous employers include Aligos Therapeutics, Second Genome, Alio Biopharma, Portola Pharmaceuticals, and InterMune. He received his M.D. from Duke University and graduated (summa cum laude) with a B.S. in biochemistry and cell biology from the University of California, San Diego.